Last reviewed · How we verify
NCT04495582
Long-term Follow-up of Phase 1 Clinical Trial of CS10BR05(CS10BR05-MSA101)
trial in Multiple System Atrophy in 8 participants. Completed in 25 September 2024.
25 September 2024
Quick facts
| Lead sponsor | Corestemchemon, Inc. |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 8 |
| Start date | 28 August 2018 |
| Primary completion | 25 September 2024 |
| Estimated completion | 25 September 2024 |
| Sites | 1 location across South Korea |
Conditions studied
- Multiple System Atrophy — all drugs for Multiple System Atrophy →
Sponsor
Corestemchemon, Inc. — full company profile →
Who can join
Eligibility, any sex, with Multiple System Atrophy. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The study purpose is conducting follow-up surveillance for the incidence of adverse events and efficacy of subjects participated in phase 1 trial to evaluate the safety and tolerability of autologous bone marrow-derived mesenchymal stem cells (CS10BR05) in subjects with Multiple System Atrophy until 60 months from administering investigational product (IP).
Publications & conference data
4 peer-reviewed publications reference this trial (live from Europe PMC):
-
The Clinical Trials of Mesenchymal Stromal Cells Therapy.
Kouchakian MR, Baghban N, Moniri SF, Baghban M, et al · · 2021 · cited 30× · PMID 34745268 · DOI 10.1155/2021/1634782 -
Multiple system atrophy: an update and emerging directions of biomarkers and clinical trials.
Liu M, Wang Z, Shang H. · · 2024 · cited 19× · PMID 38483626 · DOI 10.1007/s00415-024-12269-5 -
Current experimental disease-modifying therapeutics for multiple system atrophy.
Lemos M, Wenning GK, Stefanova N. · · 2021 · cited 13× · PMID 34398313 · DOI 10.1007/s00702-021-02406-z -
[Neuroprotective treatment of idiopathic, genetic and atypical Parkinson's disease with alpha-synuclein-Pathology].
Levin J, Nübling G, Giese A, Janzen A, et al · · 2021 · cited 1× · PMID 34735584 · DOI 10.1007/s00115-021-01220-y
Verify or expand the search:
- PubMed search for NCT04495582
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Multiple System Atrophy
Currently open trials in the same condition.
- NCT07197866 — An Extension Trial to Test if TEV-56286 is Effective in Relieving Multiple System Atrophy · Phase 2 · recruiting
- NCT06868628 — A Phase 2a Study of Foralumab Nasal in Patients With Multiple System Atrophy (MSA) · Phase 2 · recruiting
- NCT07353463 — Shanghai Clinical Cohort - Parkinson's Disease (Reserve) · recruiting
- NCT06848231 — A Phase 2 Study of YA-101 in Patients With Multiple System Atrophy · Phase 2 · recruiting
- NCT06683365 — Autologous suraL nervE Grafting to the Substantia nigrA in Patients With Synuclienopathies · Phase 1 · recruiting
Other Corestemchemon, Inc. trials
Trials by the same sponsor.
- NCT06676423 — Evaluate the Safety of Neuronata-R® Inj. Suspended With HypoTHermosol® FRS (HTS-FRS) in Patients With ALS · Phase 1 · completed
- NCT04745299 — Evaluation the Efficacy and Safety of Mutiple Lenzumestrocel (Neuronata-R® Inj.) Treatment in Patients with ALS · Phase 3 · active not recruiting
- NCT03265444 — Safety and Tolerability of CS10BR05 Inj. in Subjects with Multiple System Atrophy · Phase 1 · completed
- NCT04522505 — Long-term Follow-up for Evaluating the Safety of CS20AT04 in Subject with Lupus Nephritis · completed
- NCT03174587 — Evaluate the Safety of CS20AT04 Inj. in Subjects With Lupus Nephritis · Phase 1 · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04495582 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Corestemchemon, Inc.
- Last refreshed: 7 January 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04495582.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing